Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ramipril/Hydrochlorothiazide 10mg/25mg vs Tritace® Plus in Healthy Volunteers
NCT05685277Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ramipril and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration (Cmax) and Area Under the Curve from time 0 to 72 hours. Started Dec 2022; status: completed.
02
Drugs
ramiprilhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05685277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685277.